BRAZIL SUSPENDS CLINICAL TRIALS OF INDIAN VACCINE COVAXIN

Tue 27 July 2021:

The Brazilian Health Regulatory Agency Anvisa canceled clinical trials of Indian vaccine Covaxin after the manufacturer informed it about the change of a local partner, none of the volunteers received it.

“The termination of the company’s permit to present the vaccine in the country makes it impossible to comply with the rules governing the conduct of clinical trials of vaccines,” according to a statement on the agency’s website.

Anvisa earlier suspended clinical trials of Covaxin after the manufacturer announced the change of a local partner.

Brazilian volunteers did not have time to administer the vaccine.

Graft allegation or partnership problem?

The Bolsonaro government faced allegations of corruption regarding its agreement with Bharat Biotech which is still under investigation.

Whistleblowers from Brazil’s health department said there was pressure from higher authorities regarding the Bharat Biotech deal. It was also alleged that Pfizer was giving vaccines to Brazil at a cheaper rate.

Following this, the deal was cancelled and the Brazilian government said that there was no corruption as no money was paid to Bharat Biotech. Bharat Biotech also confirmed that it has neither received any advance payment from the Brazilian government nor supplied any vaccine.

———————————————————————————————————————-

FOLLOW INDEPENDENT PRESS:

TWITTER (CLICK HERE)
https://twitter.com/IpIndependent